Key result
Statin treatment during pregnancy was not associated with increased risk for overall congenital anomalies but was linked to a 40% higher risk of cardiac malformations and 50% higher risk of spontaneous abortions.
Why the study?
The effect of statin exposure during pregnancy on congenital anomalies and spontaneous abortions required assessment.
Does statin exposure during pregnancy increase the risk of congenital anomalies or spontaneous abortions in pregnant women?
Systematic Review (n=899,727)
Yes
Does statin exposure during pregnancy increase the risk of congenital anomalies or spontaneous abortions in pregnant women?
Statin exposure during pregnancy is not associated with an increased risk of overall congenital anomalies, supporting the re-evaluation of statin therapy in pregnant patients who may derive significant cardiovascular or obstetric benefit.
Answers are grounded in this paper and cite their sources.
Statin exposure in pregnancy may raise cardiac malformation and abortion risks; leaves open whether randomized trials would support re-evaluation of current avoidance.
Objective: To assess the effect of statin exposure during pregnancy on congenital anomalies and spontaneous abortions. Data sources: Electronic databases were searched from inception to January 2022. Study Eligibility Criteria: Cohort studies and randomized controlled trials (RCTs) evaluate the effect of treatment with statins on congenital anomalies in general and cardiac malformations in particular. Studies evaluating spontaneous abortions were included as a secondary outcome. Study appraisal and synthesis methods: Pooled odds ratio was calculated using a random-effects model and meta-regression was utilized when applicable. Results: Twelve cohort studies and RCTs were included in the analysis. Pregnancy outcomes of 2,447 women that received statins during pregnancy were compared to 897,280 pregnant women who did not. Treatment with statins was not associated with a higher risk of overall congenital anomalies (Odd Ratio = 1.1, CI (0.9–1.3), p = 0.33, I2 = 0%). Yet, cardiac malformations were more prevalent among neonates born to statins users (OR = 1.4, CI (1.1–1.8), p = 0.02, I 2 = 0%). The risk was higher when exposure occurred during the first trimester. This finding was statistically significant in cohort studies, but not in RCTs. Statin treatment was also associated with a higher rate of spontaneous abortions (OR = 1.5, CI (1.1–2.0), p = 0.005, I 2 = 0%). In meta-regression analysis, no significant association between lipophilic statins and the rate of congenital anomalies was found. Conclusion: Overall, treatment with statins during pregnancy was not associated with an increased risk of congenital anomalies. A slight risk elevation for cardiac malformation and spontaneous abortions was seen in cohort studies but not in RCTs. Systematic Review Registration: clinicaltrials.gov , identifier [CRD42020165804 17/2/2020] The meta-analysis was presented online at 42nd annual meeting of SMFM. January 31-5 February 2022.
No takes yet. Share an insight, caveat, or question.
Hirsch et al. (2022) conducted a systematic review in congenital anomalies and spontaneous abortions (n=899,727). Statins vs. No treatment was evaluated on Overall congenital anomalies (OR 1.1, 95% CI 0.9-1.3, p=0.33). Statin treatment during pregnancy was not associated with increased risk for overall congenital anomalies but was linked to a 40% higher risk of cardiac malformations and 50% higher risk of spontaneous abortions.
Synapse has enriched 10 related papers. Consider them for comparative context: